Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Operations: 2015-2025

Historic Cash from Operations for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$76.9 million.

  • Intellia Therapeutics' Cash from Operations rose 9.36% to -$76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$410.6 million, marking a year-over-year decrease of 15.11%. This contributed to the annual value of -$348.9 million for FY2024, which is 11.47% up from last year.
  • Intellia Therapeutics' Cash from Operations amounted to -$76.9 million in Q3 2025, which was up 22.81% from -$99.6 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Cash from Operations high stood at -$52.4 million for Q1 2021, and its period low was -$148.9 million during Q1 2025.
  • In the last 3 years, Intellia Therapeutics' Cash from Operations had a median value of -$93.1 million in 2023 and averaged -$97.1 million.
  • Per our database at Business Quant, Intellia Therapeutics' Cash from Operations tumbled by 192.27% in 2021 and then surged by 35.58% in 2024.
  • Intellia Therapeutics' Cash from Operations (Quarterly) stood at -$54.7 million in 2021, then crashed by 64.44% to -$89.9 million in 2022, then decreased by 3.54% to -$93.1 million in 2023, then grew by 8.45% to -$85.2 million in 2024, then grew by 9.36% to -$76.9 million in 2025.
  • Its Cash from Operations was -$76.9 million in Q3 2025, compared to -$99.6 million in Q2 2025 and -$148.9 million in Q1 2025.